Search

Background: Lichenoid drug eruption (LDE) is an uncommon cutaneous adverse drug reaction, where a variety of drugs used in day-to-day clinical practice have been implicated. Objective: To describe the clinico-demographic characteristics of patients with LDE and to identify the most likely drugs involved. Methods: In this prospective, observational study, consecutive patients with LDE presenting to the dermatology department of a tertiary teaching hospital were included. The clinico-demographic profile of patients with LDE and implicated drugs was noted. Treatment of drug reaction along with outcome was also documented. Naranjo adverse drug reaction probability scale was used for causality assessment of the drug reactions. A thorough literature review on LDE was also undertaken due to the paucity of existing literature. Results: A total of 15 patients (11 males and 4 females) with LDE were evaluated. Their age ranged from 37 to 61 years, with a mean of 51.53 ± 7.59 years. Anti-hypertensive medications (40) were the most common culprit agent, followed by antitubercular drugs (33.4), anti-diabetic agents (13.3), and others (13.3). The latent period (time from drug initiation to the appearance of a cutaneous eruption) varied from 15 days to 6 months (mean 2.2 months). Cutaneous involvement was generalized in 73.4 and photo-distributed lesions in 26.6. Drug provocation test was done to identify the culprit drug. According to the Naranjo adverse drug reaction probability scale, one-third of LDEs were 'definite,' whereas two-thirds were designated as 'probable.' Conclusion: LDE is more common in the elderly population. The latent period is comparatively longer in LDE than in other common drug reactions. Prompt recognition and withdrawal of suspected drug are essential to minimize disease morbidity. Keywords: Cutaneous adverse drug reaction, lichenoid drug eruption, Naranjo causality assessment, Author(s): Dibyendu B. Bhanja (corresponding author) [1]; Abheek Sil [2]; Arunasis Maiti [1]; Surajit K. Biswas [3] Introduction Cutaneous adverse drug reactions (CADR) are commonly encountered in day-to-day clinical practice, [...]

With our better understanding of the pathogenesis of various diseases, more and more drugs and biological products are being tried and tested every day. Roughly, around 40-50 novel drugs get approved by the Food and Drug Administration (FDA) for use in the general population, making it difficult for a physician to keep track of the constant changes in therapy. This article aimed to provide a compilation of all the FDA-approved new drugs for dermatological conditions and new dermatological indications of known drugs in the recent past, especially for dermatology residents and practising dermatologists. A comprehensive analysis, based on the list of new molecular entities approved by the FDA from 2020 to 2023, as well as a thorough English language literature search from 2020 to July 2023 across multiple databases (PubMed, MEDLINE, Springer Nature, Google Scholar and Cochrane) for various keywords (alone and in combination) such as 'FDA approved' OR 'recent advances in therapy' OR 'recent drugs' OR 'novel treatment' OR 'dermatology,' was performed. All data extracted were incorporated into the present compilation. A total of 33 drugs, including newly approved and newly approved indications of previously known drugs, were found. Relevant information about them has been discussed in a tabulated manner. This article provides an at a glance summarised profile of the newly FDA-approved drugs, as available in the existing literature. However, with the astonishing rate of new drugs hitting the market, more and more clinical trials are required to ensure the rational use of these agents. Keywords: Autoimmune, dermatology, drugs, FDA-approved, genetic, infections, inflammatory, malignant, new, wound healing, Author(s): Bartika Sikder (corresponding author) [1]; Abheek Sil [2] Introduction Since the beginning of time, evolution has been the only constant. As humankind has evolved in leaps and bounds, so [...]

Engagement of microribonucleic acids (miRNA) in the regulation of cutaneous cellular health and diseases is a rapidly advancing niche in dermatology basic research. miRNAs have been identified to play a key role in the pathogenesis of various cutaneous inflammatory, autoimmune and neoplastic conditions, among others. In addition, their purported role as therapeutic targets and biomarkers in diseased conditions harbours exciting news for the approaching years in clinical research. The current review outlines the possible translational role of miRNA in skin health and diseases (encompassing pathogenesis, diagnosis, biomarkers and therapy) from bench to bedside. Keywords: Biomarkers, inflammatory skin disease, microRNAs, novel therapy, pathogenesis, Author(s): Abheek Sil [1]; Disha Chakraborty (corresponding author) [2] Introduction Microribonucleic acids (miRNA) represent a family of noncoding RNAs, which consists of 19-25 nucleotides and regulates the expression of approximately [...]

Introduction: Burnout is a concerning clinical syndrome comprising excessive stress, lack of satisfaction, and a feeling of being overworked. In India, postgraduate residents who shoulder the entire burden of patient care, are prone to suffer from burnout. Only a few Indian studies have been carried out to estimate the prevalence of burnout among postgraduate resident doctors. Our study, the first of its kind from eastern India, aims to address this lacuna. Materials and Methods: This was a single-institution cross-sectional observational study carried out using an online semi-structured form comprising demographic data and the Maslach Burnout Inventory. Appropriate statistical tests were carried out to analyze the data obtained. Results: The study received a response rate of 79.2%. Of the participants, 44.1% were females, 54.9% were males, and 1% identified as other gender. The mean age (standard deviation) of the participants was 28.02 (3.67) years. Overall, 75% of the participants experienced burnout. Younger participants, females, clinical residents, those in a relationship, and 2nd year of residency reported higher emotional exhaustion. Depersonalization was associated with lower age, being in a relationship, metropolitan upbringing, and 2nd year of residency. The lower personal accomplishment was seen in those coming from metropolitan and rural backgrounds. Conclusion: Burnout has serious implications on psychological and physical health of the residents. Interventions for effective management will greatly improve the overall mental health and work performance of the junior doctors. [ABSTRACT FROM AUTHOR]

Byline: Abheek. Sil, Dibyendu. Bhanja, Avik. Panigrahi, Surajit. Biswas Sir, Epidermodysplasia verruciformis (EDV) is an inherited cutaneous disorder characterized by an increased susceptibility to specific human papilloma virus (HPV) genotypes, [...]

Byline: Dibyendu. Bhanja, Avik. Panigrahi, Abheek. Sil, Surajit. Biswas Sir, Nevus lipomatosus cutaneous superficialis (NLCS) is a rare benign cutaneous hamartoma with two clinical forms - classical and solitary type.[1] [...]

Byline: Abheek. Sil, Dibyendu. Bhanja, Avik. Panigrahi, Surajit. Biswas Sir, A 37-year-old gentleman presented with asymptomatic pigmented skin eruptions over the right side of chest for the preceding 20 years. [...]

Byline: Maitreyee. Panda, Siddhartha. Dash, Biswanath. Behera, Abheek. Sil The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) causing the 2019 coronavirus disease (COVID-19) has infected millions in recent years [...]

Byline: Vivek. Goel, Abheek. Sil, Anupam. Das Skin serves as the mirror of underlying systemic problems. The early diagnosis of subtle cutaneous clinical pointers often helps in identifying renal disorders, [...]